FDA's Controversial Aduhelm Decision Leaves ALS Patients Feeling Spurned

Matthew Herder; Max Gelman

FDA's Controversial Aduhelm Decision Leaves ALS Patients Feeling Spurned

Research output: Other contribution

Abstract

The FDA’s controversial approval of Biogen’s Aduhelm drug for Alzheimer’s disease has been met with fierce resistance from all corners of the biopharma industry, but few seem to be as upset with the decision as ALS patients and advocacy groups.

Original language	Canadian English
Publication status	Published - Jan. 1 2021

Keywords

Amyotrophic Lateral Sclerosis
Alzheimer’s Disease
Biopharmaceuticals
Food and Drug Administration

Disciplines

Food and Drug Law
Health Law and Policy
Law
Science and Technology Law

Access to Document

https://endpts.com/fdas-controversial-aduhelm-decision-leaves-als-patients-feeling-spurned/

Cite this

@misc{88c949ed11f44dbbb7fe1a14707fc710,

title = "FDA's Controversial Aduhelm Decision Leaves ALS Patients Feeling Spurned",

abstract = " The FDA{\textquoteright}s controversial approval of Biogen{\textquoteright}s Aduhelm drug for Alzheimer{\textquoteright}s disease has been met with fierce resistance from all corners of the biopharma industry, but few seem to be as upset with the decision as ALS patients and advocacy groups.",

keywords = "Amyotrophic Lateral Sclerosis, Alzheimer{\textquoteright}s Disease, Biopharmaceuticals, Food and Drug Administration",

author = "Matthew Herder and Max Gelman",

note = "Max Gelman, {"}FDA's Controversial Aduhelm Decision Leaves ALS Patients Feeling Spurned{"}, Endpoints News (18 June 2021), online: < endpts.com > [perma.cc/UZ7S-G936].",

year = "2021",

month = jan,

day = "1",

language = "Canadian English",

type = "Other",

}

TY - GEN

T1 - FDA's Controversial Aduhelm Decision Leaves ALS Patients Feeling Spurned

AU - Herder, Matthew

AU - Gelman, Max

N1 - Max Gelman, "FDA's Controversial Aduhelm Decision Leaves ALS Patients Feeling Spurned", Endpoints News (18 June 2021), online: < endpts.com > [perma.cc/UZ7S-G936].

PY - 2021/1/1

Y1 - 2021/1/1

N2 - The FDA’s controversial approval of Biogen’s Aduhelm drug for Alzheimer’s disease has been met with fierce resistance from all corners of the biopharma industry, but few seem to be as upset with the decision as ALS patients and advocacy groups.

AB - The FDA’s controversial approval of Biogen’s Aduhelm drug for Alzheimer’s disease has been met with fierce resistance from all corners of the biopharma industry, but few seem to be as upset with the decision as ALS patients and advocacy groups.

KW - Amyotrophic Lateral Sclerosis

KW - Alzheimer’s Disease

KW - Biopharmaceuticals

KW - Food and Drug Administration

UR - https://digitalcommons.schulichlaw.dal.ca/scholarly_works/1364

UR - https://endpts.com/fdas-controversial-aduhelm-decision-leaves-als-patients-feeling-spurned/

M3 - Other contribution

ER -

FDA's Controversial Aduhelm Decision Leaves ALS Patients Feeling Spurned

Abstract

Keywords

Disciplines

Access to Document

Other files and links

Fingerprint

Cite this